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Sir,
Acinetobacter bereziniae, formerly Acinetobacter genospecies 10,
has gained attention due to its emergence as a causative agent of
healthcare-associated infection. Importantly, A. bereziniae isolates
harbouring genes encoding resistance to multiple antimicrobial
agents, including carbapenems, located mainly on mobile genetic
elements, have been increasingly reported [1].
The widespread mechanism of carbapenem resistance in
Acinetobacter spp. is mediated by the production of carbape-
nem-hydrolysing class D β-lactamases (CHDLs). In particular,
carbapenem resistance in A. bereziniae has been previously
associated with the expression of metallo-β-lactamases (IMP,
VIM, SIM and NDM types) or overexpression of variants of the
intrinsic OXA-228-like [1]. To date, the blaOXA-58 gene has only
been detected in one A. bereziniae isolate each in Ireland and
Portugal [1,2]. In Brazil, the blaOXA-58 gene has been detected
sporadically in A. baumannii and A. seifertii. Herein, we report the
first detection of an OXA-58-producing A. bereziniae (Ac374/14) in
Brazil.
Strain Ac374/14 was isolated from an endotracheal aspirate
sample (106 CFU/mL) obtained from an 83-year-old female patient
diagnosed with ventilator-associated pneumonia in August 2014.
Species identification was confirmed by rpoB gene sequencing [3].
Antimicrobial susceptibility testing was performed according to
Clinical and Laboratory Standards Institute (CLSI) M100-S28 and
M07-A9 guidelines. The antimicrobial susceptibility profile is
reported in Table 1, demonstrating a multidrug-resistant pheno-
type. Carbapenemase production was confirmed by the CarbAci-
neto NP test. Multiplex PCR assay revealed that the isolate
possessed a blaOXA-58-like gene but was negative for other CHDL
genes analysed [4]. Nucleotide analysis of this amplicon showed
100% identity with a known blaOXA-58 sequence (GenBank
accession no. CP028560.1/Acinetobacter sp.).
Whole-genome sequencing of A. bereziniae Ac374/14 was
performed on an Illumina MiSeq platform (Illumina Inc., San
Diego, CA, USA) using a 300-bp paired-end library, which
generated 4 663 604 reads. These reads were subjected to
trimming and filtering using CLC Genomics Workbench software
v.11.0.1, in which reads with an average Phred quality of <30 and
with one or more ambiguities were removed. Finally, reads with a
size of <50 bp as well as the last 10 nucleotides of the 3ʹ end of each
read were removed. After trimming, 4 660 646 reads were used in the
assembly, which generated a genome coverage corresponding to ca.
233-fold based on the reference genome size of 4 509 124 bp for A.
bereziniae strain XH901 (accession no. CP018259.1). The genome ofhttp://dx.doi.org/10.1016/j.jgar.2019.08.011
2213-7165/© 2019 International Society for Antimicrobial Chemotherapy. Published byAc374/14 was assembled using CLC Genomics Workbench
software v.11.0.1 and a total of 242 contigs were generated,
comprising a total length of 4 837 458 bp with coverage depth of
160, an N50 value of 45.186, a maximum length of 154 002 bp, a
minimum length of 579 bp and a G + C content of 38.1%. Annotation
of the draft assembly was performed using Rapid Annotation
using Subsystem Technology (RAST) v.2.0 (available from
rast.nmpdr.org/), which included 4572 coding genes and 77 RNA
genes.
The acquired antimicrobial resistance genes were identified
using ResFinder 3.0 (https://cge.cbs.dtu.dk//services/ResFinder/)
available from the Center for Genomic Epidemiology. Resistome
analysis revealed the presence of genes encoding resistance to β-
lactams (blaOXA-58, blaOXA-257 and blaCARB-49), aminoglycosides [aph
(3')-VIa, ant(2”)-Ia], phenicols (floR) and sulfonamides (sulII).
Furthermore, according to RAST, point mutations in the parC,
parE, gyrA and gyrB genes and the presence of blaAmpC gene
responsible for fluoroquinolone and intrinsic β-lactam resistance,
respectively, were observed. Moreover, efflux pumps families
[resistance–nodulation–cell division (RND), major facilitator su-
perfamily (MFS), multidrug and toxic compound extrusion (MATE)
and ATP-binding cassette (ABC) superfamily] were identified.
Based on in silico analysis, the blaOXA-58 gene was found to be
flanked on either side by insertion sequence ISAba3. However, the
upstream ISAba3 sequence was interrupted by ISAba125, resem-
bling that previously reported in Acinetobacter genospecies 3 [5].
The downstream ISAba3 sequence was followed ampC and rep
sequences; the presence of a rep sequence indicates that the
blaOXA-58 gene may be located in a plasmid (Supplementary
Fig. S1).
A cluster of genes associated with colicin E (crbC-like, creB, creC
and creD), colicin V and bacteriocin production (dedA, dedE, R1, R3,
R4, R5, R8 and purF) as well as genes associated with invasion and
intercellular resistance, including active virulence operons in-
volved in protein synthesis (rv0682, rv0683, rv0684, rv0685,
rv1641, rv1642 and rv1643), DNA transcription (rv0667 and
rv0668), quinolinate biosynthesis (rv1594, rv1595 and rv1596)
and internalin-like protein were found. The virulence factors
detected in a manual inspection of the 242 contigs are included in
Table 1. In addition, the presence of adhesin genes ompA and bap
may be associated with the strong biofilm-producer phenotype of
A. bereziniae strain Ac374/14. Biofilm formation was evaluated
using the crystal violet staining method in polystyrene plates
following 24 h of incubation at 37 C, using A. baumannii ATCC
19606 and brain–heart infusion broth as positive and negative
controls, respectively.
The draft genome sequence of A. bereziniae Ac374/14 has been
deposited in DDBJ/EMBL/GenBank under accession no.
QWFV00000000. The version described in this paper is the first
version (QWFV01000000). Elsevier Ltd. All rights reserved.
Table 1
Phenotypic and molecular characteristics of extensively drug-resistant Acinetobacter bereziniae strain Ac374/14.
Phenotypic characteristics Antimicrobial susceptibility profile R: TZP, SXT, IPM, MEM, CRO, FEP, GEN, AMK, CIP
I: CAZ, LVX
S: SAM, COL, PMB, TGC
Carbapenemase production Positive
Biofilm formation capability Strong biofilm producer
Molecular characteristics Resistance genes β-Lactams: blaOXA-58, blaOXA-257, blaCARB-49, ampC
Aminoglycosides: aph(3')-VIa, ant(2”)-Ia
Phenicols: floR
Sulfonamides: sulII
Mutations in topoisomerases GyrA: Ser84Phe
GyrB: Ile171Val
ParC: Ser84Phe
ParE: Asn532Ala
Efflux systems ABC-type efflux pump (MacAB–TolC tripartite efflux pump)
RND-type efflux pumps (CmeABC, AdeABC and AdeIJK)
AcrB multidrug efflux pump
MATE family efflux pumps
MFS transporters
Virulence factors Adhesin
Alginate biosynthesis protein
Alkaline phosphatase family protein
BapA prefix-like domain-containing protein
BrnT family toxin
DotU family type IV/VI secretion system protein
Haemolysin III family protein
OmpA family protein
Patatin-like phospholipase family protein
Phospholipase (C and D)
ShlB/FhaC/HecB family haemolysin secretion/activation protein
Type I secretion C-terminal target domain-containing protein
Type II/IV secretion system protein
Type II secretion system F family protein
Type II secretion system protein (GspD, GspE, GspF, GspG, GspI, GspJ)
Type II toxin–antitoxin system (HipA family toxin, RelB/DinJ family antitoxin,
VapC family toxin, YafQ family toxin)
Type VI secretion system-associated protein
(Hcp, TagF, TssA, TssE, TssF, TssG, TssH, TssK, TssM, VgrG)
Zeta toxin
R, resistant; I, intermediate; S, susceptible; TZP, piperacillin/tazobactam; SXT, trimethoprim/sulfamethoxazole; IPM, imipenem; MEM, meropenem; CRO, ceftriaxone; FEP,
cefepime; GEN, gentamicin; AMK, amikacin; CIP, ciprofloxacin; CAZ, ceftazidime; LVX, levofloxacin; SAM, ampicillin/sulbactam; COL, colistin; PMB, polymyxin B; TGC,
tigecycline; ABC, ATP-binding cassette; RND, resistance–nodulation–cell division; MATE, multidrug and toxic compound extrusion; MFS, major facilitator superfamily.
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